Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other…

ELK CITY, Idaho, Aug. 11, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data and a patent filing describing the superior ability of JadiCell adult stem cells to other stem cell types in terms of stimulating production of new brain cells in an animal model of inflammation. The process of producing new brain cells is termed "neurogenesis" and is an active area of research for the Company.

"We saw that increasing doses of double stranded RNA, which mimics viral induced inflammation, was associated with decreased neurogenesis, which is to be expected. Shockingly, out of the stem cells tested, only the JadiCells were capable of stimulating neurogenesis under conditions of inflammation" stated Dr. James Veltmeyer, Chief Medical Officer of the Company. "These data suggest the possibility that JadiCells may be useful not only for patients with acute COVID-19, which we will test in our upcoming clinical trial, but may also have the potential to fight the long-term consequence of this infection."

"We are eager to explore collaborations with other neurological companies. One interesting thing about the filed patent was the embodiment of combining JadiCells with various existing drugs such as oxytocin, human chorionic growth hormone, and SSRIs" said Famela Ramos, Vice President of Business Development for the Company.

In previous studies the Company has demonstrated the superior activity of JadiCell to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell was shown to be 100% effective in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In patients over the age of 85 the survival rate was 91%1.

"Given we are getting closer to starting our Phase I/II CTE2 and our Phase III COVID trial, the validation that our cells are more potent than other adult stem cells for the brain is very promising" said Timothy Dixon, President and CEO of the Company and co-inventor. "We are enthusiastic about the success of the JadiCells because of the following characteristics: a) long history of safety data; b) what appears to be superior efficacy data as compared to other stem cells in preclinical models; c) low cost of production; and d) promising human data."

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1Therapeutic Solutions International Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell Universal Donor COVID-19 Therapy 2 Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell Chronic Traumatic Encephalopathy (CTE) Clinical Trial

[emailprotected]

SOURCE Therapeutic Solutions International

therapeuticsolutionsint.com

Originally posted here:
Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other...

Atf3 and Rab7b genes drive regeneration in mature cells – Baylor College of Medicine News

When an injury occurs, damaged cells need to be replaced. Stem cells, known as the go-to cells when new specialized cells need to be produced, are rare in adult tissues, so the job often falls to differentiated, or mature, cells.

Dr. Jason Mills and his lab have been working on identifying the genes driving mature cells to return to a regenerative state, a process called paligenosis.

My lab has been promoting the idea that given that cells in all organs use similar functions like mitosis and apoptosis, theres likely to be a conserved genetic program for how mature cells become regenerative cells, said Mills, senior author of the study and professor of medicine gastroenterology,pathology and immunologyandmolecular and cellular biologyat Baylor. The research was conducted while his lab was atWashington University School of Medicine in St. Louis.

To begin paligenosis and reenter the cell cycle, mature cells must first go through the process of autodegredation, breaking down larger structures used in specialized cell function. Mills and his team, led by first author Dr. Megan Radyk, a postdoctoral associate at the Washington University School of Medicine in St. Louis at the time of research, found that the genes Atf3 and Rab7b are upregulated in gastric and pancreatic digestive-enzyme-secreting cells of mice during autodegredation, and return to normal expression before mitosis.

The researchers showed that Atf3 activates Rab7b, which directs lysosomes to begin dismantling cell parts not needed for regeneration. But when Atf3 was not present, Rab7b did not trigger autodegredation.

The team also found Atf3 and Rab7b expression were consistent in paligenosis across other organs and organisms. Similar gene expression also appeared in precancerous gastric lesions in humans. According to Mills, the discoveries in this research are foundational to understanding how repetitive injury and paligenosis may impact cancer.

The more tissue damage you have, the more youre calling mature cells back into regeneration duty, said Mills, co-director of theTexas Medical Center Digestive Disease Center. Theres emerging evidence that, when these cells go through paligenosis, they dont check for DNA damage well. The cells are storing DNA mutations when they return to their differentiated function. Over time, they become so damaged that they cant go back to normal function and instead keep replicating.

Its our belief that paligenosis is at the heart of cancer development.

This research also provides groundwork for potential therapeutic targets. Existing drugs like hydroxychloroquine can be used to inhibit autodegredation, therefore stopping paligenosis.

According to Mills, further study is required to determine whether drugs targeting autodegredation can be used in conjunction with cancer treatments to stop cells from replicating.

The complete study is published in EMBO Reports.

For a full list of authors, their contributions to this work and sources of support, see the publication.

By Molly Chiu

Here is the original post:
Atf3 and Rab7b genes drive regeneration in mature cells - Baylor College of Medicine News

U of T’s Medicine by Design helps unite international researchers working to map every human cell – News@UofT

TheHuman Genome Project,a large-scale international effort to determine the complete DNA sequence that defines the human body, took more than 12 years to complete and involved thousands of researchers.

Now,a similar effort is underway to map each of the trillions of cells in the human body.

The Human Cell Atlas(HCA) would be acomprehensive map of cells that has the potential to rapidly advance the understanding of human health and the diagnosis, monitoring and treatment of disease, according to Gary Bader,a computational biologist and professor at the University of Torontos Donnelly Centre for Cellular and Biomolecular Research and the department of molecular genetics in the Temerty Faculty of Medicine.

This project will likely be larger than the Human Genome Project, and it requires a massive international effort. No single individual or institute could do this on their own, he says. Its multi-disciplinary in nature, and pulls in people from genomics and technology development, basic biology, clinical research, computational biology and ethics.

We encourage participation from all countries and relevant scientific communities.

Bader, who is on the organizing committee for HCA, is helping to co-ordinatea scientific meeting of the HCA from Aug. 25 to 27. The meeting will focus on human development and pediatrics, mapping the body from conception to adolescence. Medicine by Design is a lead sponsor of the meeting, along with theChan Zuckerberg Initiativeand others.

Bader says the August meeting will bring together groups of people who are working on critical questions about cell types and states during human development.

Were aiming to deliver a highly interactive meeting that will provide plenty of opportunities for virtual face-to-face interaction in breakout discussion sessions, Bader says. A silver lining of having the meeting online instead of in-person, as was originally planned, is that there are no space restrictions. It can be open to anyone who wants to attend. Also, there are no travel costs for attendees, and we are able to offer registration free of charge.

Session topics will include: understanding cellular decision-making during development;lineage tracing; clonal evolution; tagging and its applications;and developmental origins of health outcomes over a lifespan. There will also be a session on regenerative medicine, led byGuoji GuoandJason Rock, focusing on how developmental and pediatric single cell atlas data can shed light on tissue aging and repair processes.

Regenerative medicine uses stem cells to replace diseased tissues and organs, creating therapies in which cells are the biological product. Regenerative medicine can also mean triggering stem cells that are already present in the human body to repair damaged tissues or to modulate immune responses. Increasingly, regenerative medicine researchers are using a stem-cell lens to identify critical interactions or defects that prepare the ground for disease, paving the way for new approaches to preventing disease before it starts.

There is strong evidence that well have to really understand development to live up to regenerative medicines key aims, Bader says. There are questions we dont know the answer tofor example, why do children heal better than adults? These answers are essential for researchers who are developing stem cell therapies or ways to encourage self-repair in the body.

The HCA group is mapping 14 organ systems, each organized into its own bio network. For instance, the gut, heart and kidney each have their own bio network, comprisingresearchers that focus on that specific system. Bader is part of the liver bio network.

Bader, along with the Temerty Faculty of Medicine Associate ProfessorSonya MacParlandand ProfessorIan McGilvray a scientist,and surgeon and senior scientist, respectively,at University Health Network (UHN) are part of a Medicine by Design collaborative research team that, in 2018,created the firstmap of human liver cells at the molecular level. They are currently part of the large, Medicine by Design-funded team projectstudying how to harness the livers power to regenerate.

The liver map represents the first time a human organ has been charted at the single-cell level. It illuminated the basic biology of the liver in ways that could eventually increase the success of transplant surgery and enable powerful regenerative medicine treatments for liver disease such as regenerating the liver with stem cells.

This is a tool that can be used by researchers who are developing cells in the lab. For instance, a U of T and UHN teamrecently published work that showed they can develop functional blood vessel cells found in the liver. This drew on our liver map work, which provided a benchmark for those researchers to compare their cells with adult human liver cells, says Bader. HCA continues to expand this work for example in pediatricsand it will become a fundamental resource for regenerative medicine researchers.

Medicine by Design is sponsoring the HCA meeting in August because its an opportunity to engage with the international effort on human cell mapping, which creates new scientific collaborations for the Medicine by Design community.

Moreover, the HCA informs new directions in regenerative medicine research, says Michael Sefton, executive director of Medicine by Design and aUniversity Professorin the department of chemical engineering and applied chemistry in the Faculty of Applied Science & Engineering and theInstitute of Biomedical Engineering.

This international event will connect fields and people that traditionally dont work together, says Sefton, whose lab is located at the Donnelly Centre for Cellular and Biomolecular Research. A massive collaborative undertaking is whats necessary to bring HCA to fruition, and Medicine by Design is proud to support this effort. We cant overstate how much the HCA project could advance and transform regenerative medicine.

Bader says in addition to the opportunities for scientific learning, the event could have other benefits for attendees.

One of the advantages to attending the HCA meeting is the opportunity to network and potentially find out about funding opportunities one might not be aware of otherwise. Its a great opportunity for researchers to connect beyond their local collaborations.

Funded by a $114-million grant from theCanada First Research Excellence Fund, Medicine by Design brings together more than 150 principal investigators at U of T and its partner hospitals to advance regenerative medicine discoveries.

Read more from the original source:
U of T's Medicine by Design helps unite international researchers working to map every human cell - News@UofT

Mesenchymal Stem Cells Market Witnesses Upward Trend with High Prevalence of Parkinson’s Disease The Manomet Current – The Manomet Current

In the last few years, many researchers have discovered that mesenchymal stem cells (MSCs) hold the key to treating many serious diseases such as diabetes, Parkinsons disease, and multiple sclerosis. According to the study, Prevalence of Parkinsons disease (PD) across North America, published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030. Thus, high prevalence of such diseases is also expected to aid in growth of the mesenchymal stem cells market.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/720

While no one yet knows exactly how the cells work, scientists are excited about the potential benefits of using MSCs as treatment modalities. In particular, the discovery that stem cells can differentiate into other cell types has implications for the field of regenerative medicine. The potential of MSCs to provide treatments for age-related diseases is exciting. Thus, increasing geriatric population is also expected to aid in growth of the mesenchymal stem cells market.

While stem cells from adults hold the most promise for use in treating human illnesses, the discovery that adult stem cells can be directed to treat specific diseases has provided doctors with a new approach to the treatment of patients with life-threatening diseases, which in turn is expected to aid in growth of the mesenchymal stem cells market. Mesenchymal stem cells are found in the bone marrow in rich supply. Because the cells are continually being used to make blood, tissue, and organs, they are not only rich in blood, they are also rich in antigens. This allows adult stem cells to directly apply their healing properties to a host of diseases.

Adult MSCs have the potential to replace diseased or otherwise damaged adult stem cells in a variety of tissues throughout the body, including muscle, bones, and organs. Various researches have revealed exciting potential in using these cells to treat a range of debilitating diseases. For example, since MSCs can be directed to the myeloid tissues of the bone marrow, they can help to repair and regenerate tissue and organs that are injured or became infected. These studies are currently underway and have the potential to provide a major breakthrough in the treatment of many serious diseases, boosting growth of the mesenchymal stem cells market.

MSCs are also being tested to directly apply to a patients spinal cord to promote regrowth of bones and other skeletal tissues. This is done through the introduction of specialized cells into the spinal cord. Since the specialized cells that are made in the laboratory from MSCs can be directed to a number of myeloid tissues, they can provide a direct means of repairing and regenerating spinal cord injury, spinal stenosis, cervical spondylosis, spinal arthritis, etc. The long term effects of mesenchymal stem cells transplantation on the spinal cord are not yet known but the studies so far are very promising and the technology could very soon be available for clinical trials.

Buy This Research Study Report With Flat US $1000 Off @ https://www.coherentmarketinsights.com/promo/buynow/720

Major Key Players Are: Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Check Here Latest Insights: https://www.coherentmarketinsights.com/latest-insights

Read more:
Mesenchymal Stem Cells Market Witnesses Upward Trend with High Prevalence of Parkinson's Disease The Manomet Current - The Manomet Current

BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

MELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Companys metabolic ThermoStem Program. The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.

Claims granted under the new patent cover methodologies related to generating exosomes and brown adipocytes from human brown adipose-derived stem cells. Exosomes are small extracellular vesicles produced by cells that contain lipids, messenger-RNA, micro-RNA, cytokines and proteins. Therapeutic benefits of using exosomes have been demonstrated in various disease models and may provide a valuable therapeutic tool for treating disease.

We are pleased to see that we have been granted an additional patent by the USPTO for our ThermoStem Program, said Lance Alstodt, the Companys CEO. Our comprehensive portfolio of patents under our ThermoStem Program continues to expand as we develop and protect intellectual property related to large and growing markets where brown adipocyte therapeutics can be applied. Im very proud of our team, driving towards the achievement of our stated goals. The advancement of our technology is a core, fundamental value driver of our Company. Our family of intellectual property coupled with our financial reporting progress are critical factors contributing to our growth strategy.

It is expected that the exosome diagnostic and therapeutic market will reach $368 million by 2022 as the development of research, clinical tools and therapeutics continues to grow in this emerging technology.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

More:
BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -...

Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL – Cancer Network

In a long-term follow-up of an early-phase trial examining CD19.28 chimeric antigen receptor (CAR) T-cell therapy, the use of consolidative allogeneic hematopoietic stem cell transplant (alloHSCT) was associated with long-term and durable disease control in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL).

These results were based on a cohort of 20 patients who were initially treated in a dose-escalation part of a phase 1 trial (NCT01593696) examining anti-CD19 CAR T-cell therapy in patients between 1 and 30 years who have not responded to standard treatment, plus an additional 30 patients who were treated in an expansion portion. The median follow-up for all patients examined was 4.8 years and represents the longest time period examined for the use of this therapy in children and young adults with B-ALL.

We demonstrate that CD19.28 CAR T cells followed by a consolidative alloHSCT can provide long-term durable disease control in [child and young adult patients] with relapsed or refractory B-ALL, wrote the study investigators who were led by Nirali N. Shah, MD. Following alloHSCT, we observed a significant long-term [event-free survival (EFS)] with an apparent plateau and a low relapse rate, providing support for this sequential approach for long-term cure.

The complete response rate (CR) was 62.0%, with 28 of the 31 patients achieving this end point also reaching minimal residual disease (MRD) negativity by flow cytometry. The rate of CR was higher in patients with primary refractory disease (P = .0035), fewer prior lines of therapy (P = .033), and an M1 marrow (P = .0007). Additionally, CR rates were better for patients who received fludarabine/cyclophosphamidebased lymphodepletion versus other regimens, at 69% and 25%, respectively (P = .041).

The median overall survival (OS) for the cohort was 10.5 months (95% CI, 6.3-29.2 months). The median EFS was 3.1 months (95% CI, 0.9-7.7), with rates at 3 and 6 months of 52.0% (95% CI, 37.4%-64.7%) and 38.0% (95% CI, 24.8%-51.1%), respectively. Notably, median EFS was not reached in patients treated with M1 marrow versus 0.9 months in those with M2 marrow (P .0001).

Of the patients achieving MRD-negative CR (n = 28), 21 (75.0%) went on to receive consolidative alloHSCT, with a median time to transplant of 54 days from infusion (range, 42-97). The median OS from transplant day 0 was 70.2 months (95% CI, 10.4 months-not estimable) and the median EFS was not reached. The rate of EFS at 5 years was 61.9% (95% CI, 38.1%-78.8%). There were 8 deaths between 0.8 and 71 months following alloHSCT, which included transplant-related complications and/or graft-versus-host disease or infection in 6 patients and 1 patient with a complication of secondary malignancy at 3 years post-transplant. Teo patients relapsed after alloHSCT, with a cumulative risk of relapse was 4.8% (95% CI, 0.3-20.3) and 9.5% (95% CI, 1.5%-26.8%) at 12 and 24 months, respectively, with death as a competing risk.

Of note, achieving a CR was associated with greater CAR T-cell expansion and grade 3/4 cytokine release syndrome (CRS). Overall, CRS occurred in 70.0% of patients, with 9 (18.0%) having a grade 3/4 event. Neurotoxicity occurred in 10 patients (20.0%), with 4 having severe neurotoxicity.

Central nervous system involvement was effectively treated with CAR T-cell therapy all patients with a marrow response and CRS, although 1 patients did have residual disease by flow cytometry at low levels.

The authors noted that given these findings, CD19-directed CAR T-cell therapy may be considered as a bridge to alloHSCT versus standard-of-care blinatumomab (Blincyto).

Despite its more ready availability, which is not dependent on manufacturing time or success thereof, the efficacy of blinatumomab in children is lower than in adults receiving blinatumomab and also lower than remission rates following CD19-CAR T cells, using any construct, particularly for those with high-burden disease, the study author wrote. Therefore, selection of CAR T cells over blinatumomab may be advantageous in patients with higher-burden disease and [extramedullary] disease or as a salvage for blinatumomab nonresponders.

References

Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. March 25, 2021. doi: 10.1200/JCO.20.02262

Read more:
Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network

Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network – The Bisouv Network

Market Industry Reports (MIR) has published a new report titled Stem Cell Assay Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192030. According to the report the global stem cell assay market was valued at over US$ 450.0 Mn. in 2017 and is anticipated to grow at a CAGR of 19.9% from 2019 to 2030.

The updated study released on Stem Cell Assay Market by Market Industry Reports is an ideal representation of all the ongoing happenings and activities in the market to help the manufacturers and the market player in planning crucial profitable strategies for the forecast period 2020 2030. The statistical research report presents recent industry insights, product analysis, historical data, and current information for offering a better market picture to the market players. Industry players can hence plan effective strategies for future and lead the market substantially. With higher profitability, market players can penetrate deeply in the Stem Cell Assay Market and ultimately emerge by implementing right strategies.

Get sample copy of Stem Cell Assay Market at: https://www.marketindustryreports.com/pdf/8

Some of the prominent players in the Stem Cell Assay Market include:

Thermo Fisher Scientific, Promega Corporation, STEMCELL Technologies Inc., Merck KGaA, GE Healthcare, Bio-Techne Corporation, Hemogenix, Bio-Rad Laboratories, Inc., Cellular Dynamics International Inc., and Cell Biolabs Inc.

Increasing global burden of diseases such as diabetes, cancer, and others are projected to be the major factors leading to the market growth. According to the World Health Organization (WHO) in 2017, number of patients suffering from type I and type II diabetes was estimated to be over 422 million. Moreover, the disease is expected to be the seventh largest cause of death by 2030.

According to American Cancer Society, in 2017, there were over 1.6 million new cancer cases in the U.S. Hence, there exists a need for developing new treatment methods which have led to the rise in approvals of clinical trials for the stem cell based therapies.

The Stem Cell Assay Market is segmented on the basis of Product, Modality, Cancer Type, End-Users and region.

by Product & Service (Instruments, Kits) Cell Type(Adult Stem Cells, Human Embryonic Stem Cells), Application (Regenerative Medicine, Drug Discovery, Clinical Research), Type (Cell Identification, Viability, Proliferation Assay)

Have any query? Inquiry about report: https://www.marketindustryreports.com/inquiry/8

The Research Report aims to resolve the following questions related to the Stem Cell Assay Market

Table of Contents

Buy this report @ https://www.marketindustryreports.com/checkout/8

About Market Industry Reports

Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.

Contact Us-Email:[emailprotected] Phone:+ 91 8956767535 Website:https://www.marketindustryreports.com

See the original post here:
Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network - The Bisouv Network

Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News – FLA News

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem cells are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells. The adult stem cells owes multipotency and difference flexibility which can be exploited for next generation therapeutic options. Recently, scientists have also recognized stem cells in the placenta and umbilical cord blood that can give rise to several types of blood cells. Research for stem cells is being undertaken with the expectation of achieving major medical inventions. Scientists are attempting to develop therapies that replace or rebuild spoiled cells with the tissues generated from stem cells and offer hope to people suffering from diabetes, cancer, spinal-cord injuries, cardiovascular disease, and many other disorders.

The stem cell therapy market is segmented on the basis of type, therapeutic applications, cell source, and geography. On the basis of type, the stem cell therapy market is categorized into allogeneic stem cell therapy and autologous stem cell therapy. Allogeneic stem cell therapy includes transferring the stem cells from a healthy person (the donor) to the patients body through high-intensity radiation or chemotherapy. Allogeneic stem cell therapy is used to treat patients who do not respond fully to treatment, who have high risk of relapse, and relapse after prior successful treatment. Autologous stem cell therapy is a type of therapy that uses the persons own stem cells. These type of cells are collected earlier and returned in future. The use of stem cells is done to replace damaged cells by high doses of chemotherapy, and to treat the persons underlying disease. On the basis of therapeutic applications, the stem cell therapy market is segmented into cardiovascular diseases, wounds and injuries, musculoskeletal disorders, gastrointestinal diseases, surgeries, neurodegenerative disorders, and others. On the basis of cell source, stem cells therapy is segmented into bone marrow-derived mesenchyme stem cells, adipose tissue-derived mesenchyme stem cells, and cord blood or embryonic stem cells

Request For Brochure @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28262

By geography, the market for stem cell therapy is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the stem cell therapy market owing to rising awareness among people, early treatment adoption, and new product innovations. Europe is the second leading market for stem cell therapy due to development and expansion of more efficient and advanced technologies. The Asia Pacific stem cell therapy market is also anticipated to grow at an increasing rate owing to increasing healthcare spending, adoption of western lifestyles, and growth in research and development. Asia Pacific is the fastest growing region for stem cell therapy as several players have invested in the development of new stem cell technologies. These factors are expected to drive the growth of the stem cell therapy market globally during the forecast period.

Request For Custom Research https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=28262

The major player in the stem cell therapy market are Regenexx, Takara Bio Company, Genea Biocells, PromoCell GmbH, CellGenix GmbH, Cellular Engineering Technologies, BIOTIME, INC., Astellas Pharma US, Inc., AlloSource, RTI Surgical, Inc., NuVasive, Inc., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., PHARMICELL Co., Ltd, ANTEROGEN.CO., LTD., The Future of Biotechnology, and Osiris Therapeutics, Inc. Rising demand for advanced stem cell therapies will increase the competition between players in the stem cell therapy market.

Read Our Trending Press Release Below

About Us Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA Canada Toll Free: 866-552-3453 Email:sales@transparencymarketresearch.com Website:https://www.transparencymarketresearch.com/

Read this article:
Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News - FLA News

Adult Stem Cells Market Size, Share, Global Industry Overview, Challenges, Business Overview and Forecast Research Study 2024 (Effect of the COVID-19…

Overview for Adult Stem Cells Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Adult Stem Cells market focuses on encompassing major statistical evidence for the Adult Stem Cells industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Adult Stem Cells study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

Download PDF Sample of Adult Stem Cells Market report @ https://hongchunresearch.com/request-a-sample/92343

This intelligence and 2026 forecasts Adult Stem Cells industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Adult Stem Cells market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Adult Stem Cells report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Adult Stem Cells market, business trends, potential revenue sources, and upcoming market opportunities.

Key players in the global Adult Stem Cells market covered in Chapter 4: Intellicell Biosciences Inc. Globalstem Neurogeneration Capricor Inc. Caladrius Biosciences Inc. Mesoblast Ltd. Celyad Juventas Therapeutics Inc. Cytori Therapeutics Inc. Cellular Dynamics International Epistem Ltd. Brainstorm Cell Therapeutics Inc. Cellerant Therapeutics Inc. Hybrid Organ Gmbh Cellerix Sa Neuralstem International Stem Cell Corp. Beike Biotechnology Co. Ltd. Biotime Inc. Gamida Cell Ltd. Clontech

In Chapter 11 and 13.3, on the basis of types, the Adult Stem Cells market from 2015 to 2026 is primarily split into: Epithelial Stem Cells Hematopoietic Stem Cells

In Chapter 12 and 13.4, on the basis of applications, the Adult Stem Cells market from 2015 to 2026 covers: Neurodegenerative Diseases Heart Diseases Bone Diseases Others

Brief about Adult Stem Cells Market Report with [emailprotected] https://hongchunresearch.com/report/adult-stem-cells-market-size-2020-92343

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13: North America (Covered in Chapter 6 and 13) United States Canada Mexico Europe (Covered in Chapter 7 and 13) Germany UK France Italy Spain Russia Others Asia-Pacific (Covered in Chapter 8 and 13) China Japan South Korea Australia India Southeast Asia Others Middle East and Africa (Covered in Chapter 9 and 13) Saudi Arabia UAE Egypt Nigeria South Africa Others South America (Covered in Chapter 10 and 13) Brazil Argentina Columbia Chile Others

Get 20% complementary customization along with purchase of Adult Stem Cells Industry [emailprotected]https://hongchunresearch.com/check-discount/92343

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Adult Stem Cells Market

Chapter Four: Players Profiles

Chapter Five: Global Adult Stem Cells Market Analysis by Regions

Chapter Six: North America Adult Stem Cells Market Analysis by Countries

Chapter Seven: Europe Adult Stem Cells Market Analysis by Countries

Chapter Eight: Asia-Pacific Adult Stem Cells Market Analysis by Countries

Chapter Nine: Middle East and Africa Adult Stem Cells Market Analysis by Countries

Chapter Ten: South America Adult Stem Cells Market Analysis by Countries

Chapter Eleven: Global Adult Stem Cells Market Segment by Types

Chapter Twelve: Global Adult Stem Cells Market Segment by Applications

Chapter Thirteen: Adult Stem Cells Market Forecast by Regions (2020-2026)

Adult Stem Cells Market Competitive Landscape & Forecast

The study uses a competitive landscape model in terms of a variety of analytical factors such as market application sales data, sold application volume and identifying the regional distribution where the Adult Stem Cells market seems at a higher edge. By following through the capabilities & opportunities for the Adult Stem Cells marketa true sense of the market scape can be gauged. During the forecast period, it helps us clearly define the optimal or favorable fit for our readers which can further helps them adopt better strategies in terms of geographical expansion, R&D and even acquiring further product integration to successfully maneuver their business ventures.

What is COVID-19 Impact on the Adult Stem Cells Market?

While the ongoing pandemic has affected every major industry, the long term effects are projected in the forecast taking into account the following factors. Our ongoing research is amplified to include the effects of the COVID-19 impacts on every leg of the Adult Stem Cells market which further helps us push our potential paths forward.

This study delivers insights on the COVID-19 considering a variety of factors such as changed consumer behavior, latest market dynamics, analyzing purchasing patterns, re-routing supply chains and financial interventions of government bodies. This updated study for Adult Stem Cells market provides insights, analytics, estimations and forecasts considering the COVID-19 impact on the Adult Stem Cells market which can help our readers sidestep the impacts as best as they can.

If you have any special requirements, please let us know and we will offer you the report as you want.

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer Gray Manager Global Sales + 852 8170 0792 [emailprotected]

https://neighborwebsj.com/

Read the original post:
Adult Stem Cells Market Size, Share, Global Industry Overview, Challenges, Business Overview and Forecast Research Study 2024 (Effect of the COVID-19...

Be The Match encourages people of color to join bone marrow registry – KING5.com

Black patients in need of bone marrow or blood stem cell treatments have a decreased chance of matching with a donor. The Seattle branch hopes to change that.

Seattles Be The Match Collection Center opened up less than a year ago and is celebrating its 100th blood cell donation with an important message: More bone marrow donors of color are needed.

The nonprofit donation center is a part of the National Marrow Donor Program and increases the capacity to collect blood cells in the Pacific Northwest. Seattles Clinical Manager Hannah Erskine said this month is an important time to focus on the donation gap.

In the midst of Black History Month, its important to note that we frankly dont have enough Black and African American donors on the registry, said Erskin.

Only 4% of approximately 22 million donors on the registry are African American, lowering the chances that a Black patient can find a bone marrow donor who is a genetic match.

According to Be The Match data, the likelihood of finding a matched adult donor is only around 23% for an African American or Black patient, versus a 77% match rate for a white patient.

These matched bone marrow or blood stem cell transplants can help cure blood cancers like leukemia and lymphoma, as well as other blood conditions, such as sickle cell disease. Be The Match has coordinated more than 100,000 transplants.

Erskine said registering is a simple mouth swab that will be mailed to potential donors. They will be contacted if they are a match with a patient.

Being a matching blood stem cell donor can potentially save a life. The first step in changing the trend is to join the registry at http://www.bethematch.org.

Read the original post:
Be The Match encourages people of color to join bone marrow registry - KING5.com